US2023295079A1PendingUtilityA1
Isotope-enriched 3-amino-1-propanesulfonic acid derivatives and uses thereof
Assignee: RISEN SUZHOU PHARMA TECH CO LTDPriority: Mar 21, 2017Filed: Nov 23, 2022Published: Sep 21, 2023
Est. expiryMar 21, 2037(~10.7 yrs left)· nominal 20-yr term from priority
Inventors:Jiasheng LuJiamin GuXinyong LvGuowei SongDongdong WuDaiqiang HuJun GuGang ChenXiang JiXiuchun ZhangJinchao AiXianqi Kong
C07D 233/64C07C 309/14C07C 309/15C07C 323/60C07B 2200/05A61P 25/28A61P 25/00A61P 25/16C07B 59/001C07B 59/002C07D 233/61C07C 309/59Y02P20/55
77
PatentIndex Score
0
Cited by
0
References
0
Claims
Abstract
There are provided isotope-enriched compounds of Formula (I) and pharmaceutically acceptable salts or esters thereof, as well as pharmaceutical compositions thereof and methods of use thereof for prevention and treatment of amyloid-β related diseases, such as Alzheimer's disease.R1R2X—CR2—CH2—CH2—SO3H (I)
Claims
exact text as granted — not AI-modifiedWhat is claimed is:
1 . A compound of Formula (I), or a pharmaceutically acceptable salt or ester thereof:
R 1 R 2 X—CR 2 —CH 2 —CH 2 —SO 3 H (I)
where:
R 1 and R 2 are independently a hydrogen of natural abundance or a protecting group, wherein said protecting group is isotope-enriched or non-isotope enriched, said protecting group being selected from acyl, carbonyl, thiocarbonyl, and carbamoyl groups;
X is a nitrogen of natural abundance or 15 N, or a combination thereof, and
R is a hydrogen of natural abundance, a deuterium (D) or a combination thereof,
provided that at least one of X, R, R 1 and R 2 comprises an atom that is not of natural abundance.
2 .- 41 . (canceled)Join the waitlist — get patent alerts
Track US2023295079A1 — get alerts on status changes and closely related new filings.
We store only your email — no account needed. See our privacy policy.